Halozyme Therapeutics (HALO) Tax Provisions (2016 - 2026)

Halozyme Therapeutics (HALO) has 11 years of Tax Provisions data on file, last reported at $30.3 million in Q1 2026.

• Tax Provisions for Q1 2026 came in at $30.3 million, up 17.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.5 million (up 29.23% YoY), and the FY2025 annual result was $150.0 million, up 32.68% from the prior year.
• Tax Provisions declined to $30.3 million in Q1 2026 per HALO's latest filing, from $40.7 million in the prior quarter.
• Over five years, Tax Provisions peaked at $43.7 million in Q3 2025 and troughed at $7.3 million in Q2 2022.
• A 5-year average of $23.9 million and a median of $19.9 million in 2023 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2022 and 2023: Tax Provisions soared 12531.03% in 2022, then fell 11.73% in 2023.
• A 5-year view of Tax Provisions shows it stood at $13.1 million in 2022, then climbed by 20.61% to $15.8 million in 2023, then jumped by 160.99% to $41.2 million in 2024, then decreased by 1.12% to $40.7 million in 2025, then dropped by 25.68% to $30.3 million in 2026.
• Business Quant data shows HALO's Tax Provisions at $30.3 million in Q1 2026, $40.7 million in Q4 2025, and $43.7 million in Q3 2025.